Elute Intelligence appoints Steve Cable as CEO
Elute Intelligence has appointed Steve Cable as Chief Executive Officer. He has extensive experience building businesses at start-ups, mid-size firms and large companies.
Read moreHalf year results: maturing portfolio makes good commercial and technical progress
Pre-tax profits reach £1.4 million and the fair value of the equity portfolio rises 6 per cent to £35 million despite difficult market and economic conditions.
Read moreAlusid outlines plans for 2024 after raising £1.1 million
Alusid is developing premium-quality tiles with even higher levels of recycled material, as well as floor tiles, says CEO Alasdair Bremner in this Proactive video. The company is also exploring international expansion and IPO options.
Read moreOctopus backs Alusid as part of £1.1 million fundraising
Alusid now exploring IPO options and expansion into new product ranges and territories following £500,000 investment from Octopus AIM VCT plc and Octopus AIM VCT 2 plc funds.
Read moreHorns of plenty: unicorns, narwhals and the changing company valuation landscape
Once rare financial unicorns have become all too common in the past decade, but are now facing geopolitical and economic headwinds. In this presentation to premier global executive knowledge network FS Club, Chief Executive Neil Crabb explains what narwhals can teach us that unicorns can’t.
Read moreThe Vaccine Group appoints industry experts to new Advisory Board
The Vaccine Group has appointed three animal health industry experts to a new Advisory Board to support scale up of the Company’s novel vaccine platform technology.
Read moreFull year results 2023: good technical and commercial progress in challenging markets
Alusid, Nandi Proteins, Cambridge Raman Imaging, Celerum, and Fieldwork Robotics are all either generating revenues or are about to start, taking further strides forward to commercial viability. The day moves closer for a second portfolio company to follow Exscientia in launching an initial public offering or to execute a trade sale.
Read moreDame Julia King, Baroness Brown of Cambridge, to become Frontier IP Chair
Current Chair Andrew Richmond will step down from the Board of Directors at the next annual general meeting, expected to be held in December 2023.
Read moreBio-materials developer DeakinBio joins our portfolio
DeakinBio is developing advanced bio-based materials from organic waste and widely available inorganic powders. Frontier IP has taken a 32.8 per cent equity stake
Read moreExscientia’s new AI drug discovery collaboration with Merck worth up to $674 million
The collaboration will focus on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.
Read more